Go Pro
NASDAQ:ABVC

ABVC BioPharma Q2 2026 Earnings Report

ABVC BioPharma logo
$1.03 -0.05 (-4.63%)
As of 10:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ABVC BioPharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
9:30AM ET

Conference Call Resources

ABVC BioPharma Earnings Headlines

ABVC BioPharma (NASDAQ:ABVC) Trading 2.5% Higher - Time to Buy?
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
ABVC BioPharma Delays Quarterly SEC Filing
ABVC BioPharma Reports 2025 Form 10-K
ABVC BioPharma Provides Corporate and Structural Update
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens. ABVC BioPharma applies its platform to generate both personalized and off-the-shelf candidates, with preclinical and early-stage clinical studies evaluating safety, immunogenicity and preliminary efficacy.

Headquartered in Research Triangle Park, North Carolina, ABVC BioPharma operates research laboratories in North America and collaborates with academic and industry partners to advance its development programs. The company’s leadership team is composed of executives and scientists with experience in peptide chemistry, immunology and clinical development, guiding its efforts to bring new vaccine-based therapies to market.

View ABVC BioPharma Profile